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Dan T. Vogl,1 Tao Wang,2 Waleska S. Perez,2 Edward A. Stadtmauer,1
Daniel F. Heitjan,3 Hillard M. Lazarus,4 Robert A. Kyle,5 Ram Kamble,6 Daniel Weisdorf,7
Vivek Roy,8 John Gibson,9 Karen Ballen,10 Leona Holmberg,11 Asad Bashey,12
Philip L. McCarthy,13 Cesar Freytes,14 Dipnarine Maharaj,15 Angelo Maiolino,16
David Vesole,17 Parameswaran Hari2Obesity has implications for chemotherapy dosing and selection of patients for therapy. Autologous hema-
topoietic stem cell transplant (AutoHCT) improves outcomes for patients with multiple myeloma, but op-
timal chemotherapy dosing for obese patients is poorly defined. We analyzed the outcomes of 1087
recipients of AutoHCT for myeloma reported to the CIBMTR between 1995 and 2003 who received
high-dose melphalan conditioning, with or without total body irradiation (TBI). We categorized patients
by body mass index (BMI) as normal, overweight, obese, or severely obese. There was no overall effect
of BMI on progression-free survival (PFS), overall survival (OS), progression, or nonrelapse mortality
(NRM). In patients receiving melphalan and TBI conditioning, obese and severely obese patients had superior
PFS and OS compared with normal and overweight patients, but the clinical significance of this finding is
unclear. More obese patients were more likely to receive a reduced dose of melphalan, but there was no
evidence that melphalan or TBI dosing variability affected PFS. Therefore, current common strategies of
dosing melphalan do not impair outcomes for obese patients, and obesity should not exclude patients
from consideration of autologous transplantation. Further research is necessary to optimize dosing of
both chemotherapy and radiation in obese patients.
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1766 Biol Blood Marrow Transplant 17:1765-1774, 2011D. T. Vogl et al.Obesity is a potential source of variability in treat-
ment outcomes. Obesity may affect outcomes through
alterations in chemotherapy dosing and pharmacoki-
netics [4]; association with comorbidities or more ag-
gressive disease, worse stage at diagnosis, and poorer
response to chemotherapy [5,6]; or conversely, as
a marker for the absence of cancer cachexia. Because
of these overlapping and potentially contradictory
effects, understanding the effect of obesity on cancer
treatment requires careful study of specific situations
and appropriate control for confounding factors. The
effect of obesity on outcomes from chemotherapy
has been studied in other patient populations [5,7-17],
including patients undergoing hematopoietic stem
cell transplantation [18-24] but not in myeloma
patients undergoing AutoHCT.
Conditioning therapy before AutoHCT in MM
usually involves a single chemotherapeutic agent,
melphalan, given near its maximum tolerated dose,
which is based on body surface area (BSA). Although
the dose of melphalan is directly related to its toxicity
and antineoplastic efficacy, no data exist to guide dose
adjustments in obese patients receiving high-dose
melphalan. The effects of obesity on dosing changes
and their impact on posttransplantation outcomes
are important for guiding treatment decisions and fur-
ther research.SUBJECTS AND METHODS
Patients
The study population included adult recipients of
autologous peripheral blood hematopoietic stem cell
transplant for MM between 1995 and 2003 reported
to the Center for International Blood and Marrow
TransplantResearch (CIBMTR).The studypopulation
was limited to patients receiving a melphalan-based
conditioning regimenwith or without total body irradi-
ation (TBI), and to transplantations done as part of ini-
tial therapy, definedas an interval betweendiagnosis and
transplant of#18months. Planned tandemAutoHCTs
were excluded.Body Mass Index (BMI) and BSA
Obesity was defined according to BMI at the time
of transplantation. BMI was calculated as weight
(in kg)/height (in m)2 and categorized using definitions
of the WHO and National Heart, Lung, and Blood
Institute as: normal weight (18.5 # BMI\ 25), over-
weight (25 # BMI\ 30), obese (30 # BMI\ 35),
and severely obese (BMI $ 35) [25]. Underweight
(BMI\18.5) patients were excluded from the analysis
because of the small sample size (n 5 9) and the likely
complicating influence of cancer cachexia because of
severe disease. Melphalan doses were reported to theCIBMTR as total mg administered, without specific
information as to the treating physician’s intended
dose per m2 of BSA or dose modifications for any pa-
tient characteristics.We therefore also expressed doses
of melphalan as mg/m2 based on BSA calculated from
the height and the actual body weight (ABW) at time
of transplantation, using the formula developed by
DuBois and DuBois [26]. Alternative BSA calculations
were also performed using ideal body weight (IBW;
calculated as [height in m]2  22) [27] and adjusted
IBW (calculated as IBW 1 0.25  [ABW 2 IBW]).Definition of Outcomes
Overall survival (OS) from transplantation was de-
fined as the time from date of transplantation to date
of death, with survivors censored at the time of last
contact. Nonrelapse mortality (NRM) was defined as
death occurring in the absence of relapse/progressive
disease and summarized by the cumulative incidence
estimate with relapse/progression as the competing
risk. Relapse/progression was defined as the time to
first evidence of progression of myeloma according
to the standard European Blood and Marrow Trans-
plant (EBMT)/International Bone Marrow Transplant
Registry (IBMTR) criteria [28,29] and summarized by
the cumulative incidence estimate with NRM as the
competing risk [29]. Progression-free survival (PFS)
was defined as survival without progressive disease or
relapse from complete response.Statistical Analysis
Patient-, disease-, and transplant-related variables
were described and compared among the BMI groups
using the chi-square statistic for categoric variables
and the Kruskal-Wallis test for continuous variables.
Univariate probabilities of PFS andOSwere estimated
using the Kaplan-Meier method with the log-rank
test used for univariate comparisons [30]. Univariate
probabilities of NRM and relapse/progression were
calculated using cumulative incidence curves to ac-
commodate competing risks [31].
The hazard ratios of the main outcome of interest
(BMI subgroups) and other risk factors potentially
associated with relapse/progression, treatment failure,
and survival were modeled using Cox proportional haz-
ards regression [30,32]. A stepwise forward/backward
model selection approach was used to identify
significant risk factors, with the main effect for BMI
forced into the model at each step and factors
significant at a 5% level kept in the final model.
Potential interactions between the main effect and all
significant risk factors were tested at the significance
level of 0.015, by which criterion a significant
interaction was found between the TBI and BMI group
for progression and PFS, and borderline (P 5 .012) for
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were therefore constructed including this interaction.
Adjusted probabilities of PFS and OS were generated
from the final Cox models stratified on the BMI
group, and weighted averages of covariate values using
the pooled sample proportion as the weight function
and were used to estimate likelihood of outcomes
in populations with similar prognostic factors.
Examination for center effects using a random effects
or frailty model found no evidence of a center effect.
We compared the factors associated with melphalan
dose reduction using logistic regression models and
the effect of dose reduction on PFS using Cox
proportional hazards models.
Statistical analyses were performed using the
statistical package of SAS version 9 (Cary, NC). All
P values are 2-sided and reported without adjustment
for multiple comparisons.RESULTS
Study Population
The 1087 patients with MM who met study inclu-
sion criteria included 292 of normal weight, 472 over-
weight, 198 obese, and 125 severely obese. Median
follow-up of survivors was 63 (range: 1-144) months,
61 (3-144) months, 60 (3-133) months, and 59 (3-131)
months for the respective BMI categories.
Baseline patient characteristics are shown in
Table 1. Obese patients were younger than their non-
obese counterparts. There was a higher prevalence of
diabetes among obese patients. Obese transplant re-
cipients also had less frequent hypercalcemia, severe
anemia, and renal insufficiency. A higher proportion
of severely obese patients were in complete or partial
response at time of transplantation.Outcomes after Autologous Transplantation
In the study population as a whole, there was no
clear effect of BMI on PFS, OS, progression, or
NRM. We identified a statistically significant interac-
tion between BMI and conditioning regimen for PFS
and progression. Among those receiving melphalan
alone, there was no clear association between BMI
and these outcomes, with PFS at 5 years of 17% of nor-
mal weight patients, 18% of overweight patients, 21%
of obese patients, and 14% of severely obese patients
(P 5 .65). Among those receiving melphalan and
TBI, obese and severely obese patients had superior
PFS and OS than normal and overweight patients,
with PFS at 5 years of 23% in normal weight patients,
17% in overweight patients, 43% in obese patients, and
55% in severely obese patients (P 5 .005). P values
for the interactions between BMI and conditioning
regimen were highly significant for PFS (P 5 .0063)and progression (P 5 .0085), with borderline signifi-
cance for OS (P 5 .012), but not significant for NRM
(P 5 .43). The effect of BMI on outcomes after trans-
plantationwas therefore restricted to patients receiving
melphalan with TBI, with obese patients having better
outcomes that were mediated primarily through a low-
er risk of disease progression.
To exclude confounding by baseline imbalances,
we constructed multivariable models of PFS, OS,
and progression using all potential confounders.
These models included each variable individually, in
groups of related variables, and in a single model using
all variables, none of which showed any evidence of
confounding, with no change in the estimate of effect
of BMI on outcomes for patients receiving melphalan
alone or melphalan with TBI (data not shown). Final
multivariable models, constructed using a forward/
backward stepwise algorithm, confirmed the effects
of BMI on PFS, progression, and OS, as shown in
Tables 2 to 4. A multivariate model for NRM (not
shown) showed no evidence of confounding, and
BMI did not have any clear effect on this outcome.
Estimated probabilities of all these outcomes based
on the final multivariate models are shown in Figure 1.Effects of Melphalan Dose and Dose Reduction
Doses of melphalan were compared among BMI
groups as absolute doses and as doses per m2 of
BSA calculated using ABW, IBW, and adjusted
IBW. As expected with BSA-based dosing, patients
who were more obese received higher absolute doses
of melphalan, both when melphalan was given alone
and when it was given in combination with TBI
(Figure 2). With both conditioning regimens, patients
who were more obese received a lower dose per m2 of
actual BSA (ie, using ABW to calculate BSA). Using
IBW or adjusted IBW to calculate BSA resulted in
normalized doses that were closer among BMI
groups, although there were still significant differ-
ences among the groups. When compared on the ba-
sis of melphalan dose per kg of body weight [33],
more obese patients received a lower dose of melpha-
lan/kg of ABW.
We further investigated the effect of chemotherapy
dosing decisions in obese patients. A full dose of
melphalan was defined as 200 mg/m2 (calculated by
ABW) for conditioning regimens using melphalan
alone and as 140 mg/m2 for transplants using melpha-
lan with TBI. A reduced dose of melphalan was defined
as\90%of the full dose.Using this definition, reduced
doses of melphalan were given to 78% of severely
obese, 56% of obese, 32% of overweight, and 11% of
normal weight patients (P \ .0001). Therefore, the
odds of dose reduction were 30 (95% confidence
interval [CI]: 17-53) times higher for severely obese
patients, 11 (95% CI: 7-17) times higher for obese
Table 1. Baseline Characteristics
Normal Overweight Obese Severely Obese P-Value
Number of patients 292 472 198 125
Median age at transplantation 58 58 56 55 .005
Male sex 49% 62% 64% 45% <.01
Race* .02
Caucasian 81% 82% 78% 82%
African-American 10% 9% 13% 16%
Other 8% 7% 7% 2% .45
History of coronary artery disease* 4% 7% 4% 6%
History of diabetes mellitus* 13% 17% 24% 21% .08
History of hypertension* 40% 47% 55% 51% .11
History of other malignancy* 7% 10% 7% 9% .70
Immunochemical subtype of myeloma* .27
IgG 56% 55% 58% 59%
IgA 21% 20% 20% 30%
Light chain 17% 18% 17% 9%
Nonsecretory 5% 6% 3% 2%
Durie-Salmon stage at diagnosis* .10
I 5% 7% 6% 8%
II 27% 29% 35% 39%
III 68% 64% 59% 53%
Beta-2 microglobulin (mg/L)* .09
<3.5 53% 55% 68% 62%
>5.5 27% 30% 18% 23%
Albumin at diagnosis <3.5 g/dL* 52% 46% 49% 55% .29
Calcium >10.5 mg/dL at diagnosis* 24% 21% 12% 15% .01
Hemoglobin at diagnosis* .03
<8.5 g/dL 20% 17% 12% 12%
8.5-10 g/dL 28% 20% 24% 22%
>10 g/dL 52% 63% 64% 66%
Lytic bone lesions* 80% 82% 77% 73% .22
Creatinine $2 mg/dL at diagnosis* 20% 22% 12% 13% .015
Creatinine $2 mg/dL at transplantation* 7% 6% 6% 3% .34
Interval from diagnosis to transplantation <12 mos 88% 89% 89% 88% .87
Number of lines of therapy before transplantation .78
1 65% 65% 66% 73%
2 27% 26% 26% 22%
$3 8% 9% 9% 6%
Karnofsky performance status at transplantation* 0.71
<80 13% 9% 9% 9%
80 23% 24% 27% 25%
90-100 64% 67% 64% 66%
Disease status at time of transplantation* 0.024
Complete or partial response 75% 77% 77% 79%
Minor or no response 21% 21% 23% 20%
Relapse or progression 5% 2% 0% 2%
Conditioning regimen 0.22
Melphalan high dose 85% 87% 89% 82%
Melphalan + TBI 15% 13% 11% 18%
Year of transplantation 0.57
1995-2000 46% 41% 41% 41%
2001-2003 54% 59% 59% 59%
Median follow-up of survivors, months (range)† 63 (1-144) 61 (3-144) 60 (3-133) 59 (3-131)
TBI indicates total body irridiation.
*Percentages shown are of patients with available data. Data are missing for race (19 patients), history of coronary artery disease (487), history of hy-
pertension (481), history of diabetes (481), history of other malignancy (489), immunotype (37), Durie-Salmon stage (27), beta-2 microglobulin (496),
albumin (286), calcium (241), hemoglobin (107), lytic bone lesions (139), creatinine at diagnosis (215), creatinine at transplantation (52), Karnofsky score
(39), and disease status at time of transplantation (7).
†Completeness index 5 90%.
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weight patients, compared with normal weight pa-
tients. Dose reduction was also more common for
patients with renal insufficiency (odds ratio [OR] 2.0,
95% CI: 1.2-3.4), history of hypertension (OR: 1.7,
95% CI: 1.2-2.4) or diabetes (OR: 1.8, 95%
CI: 1.2-2.7), non-Caucasian race (OR: 1.4, 95% CI:
1.1-2.0), or transplant in the period from 2001-2003(OR: 1.4 compared with transplantation in 1995-2000,
95% CI: 1.1-1.8). Dose reduction was not associated
with other variables, including age, performance status,
number of prior therapies, or disease status at time of
transplantation.
There was no evidence of an effect of melphalan
dose reduction on PFS. Receipt of a reduced dose of
melphalan was associated with a univariate hazard
Table 2. Multivariate Analysis of Progression-Free Survival
N* Hazard Ratio for Treatment Failure 95% Confidence Interval P Value
BMI:†
Melphalan alone
Normal 243 1.00 Poverall 5 .16
Overweight 397 0.90 0.75 1.08 .24
Obese 175 0.85 0.68 1.07 .16
Severely obese 99 1.13 0.87 1.47 .37
Melphalan/TBI
Normal 44 1.00 Poverall 5 .006
Overweight 62 0.92 0.60 1.40 .69
Obese 20 0.49 0.27 0.90 .021
Severely obese 22 0.39 0.20 0.76 .005
Other significant covariates:
Immunochemical subtype
IgG 576 1.00 Poverall 5 .010
IgA 219 1.37 1.15 1.63 <.001
Light chain 168 1.06 0.87 1.29 .59
Others 63 0.96 0.71 1.31 .81
Unknown 36 1.00 0.67 1.48 .99
Time from diagnosis to transplantation
<12 months 940 1.00
12-18 months 122 1.39 1.13 1.72 .002
BMI indicates body mass index; TBI, total body irradiation.
*Seven patients were excluded from the model for missing information on vital status, 1 patient was excluded for missing information on time from
diagnosis to transplantation, and 17 patients were excluded because of missing information on time to progression.
†P value for interaction between BMI and TBI 5 0.0056.
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a multivariate analysis (controlling for renal function,
performance status, age, race, gender, history of
hypertension or diabetes, disease status, and year of
transplantation), the hazard ratio associated with mel-
phalan dose reduction was 0.88 (95% CI: 0.70-1.10).
We also found no effect of melphalan dose on PFS,
regardless of whether the dose was specified as total
melphalan administered, as the dose per m2 of BSATable 3. Multivariate Analysis of Progression of MM
N* Hazard Ratio for Progr
BMI:†
Melphalan alone
Normal 244 1.00
Overweight 397 0.85
Obese 175 0.87
Severely obese 99 1.18
Melphalan/TBI
Normal 44 1.00
Overweight 62 0.96
Obese 20 0.54
Severely obese 22 0.43
Other significant covariates:
Immunochemical subtype
IgG 576 1.00
IgA 220 1.44
Light chain 168 1.06
Others 63 0.95
Unknown 36 1.12
Disease status at transplantation
CR/PR 812 1.00
Minor or no response 227 1.16
Relapse/progression 24 1.84
BMI indicates body mass index; TBI, total body irradiation; CR, complete resp
*Seven patients were excluded from the model for missing information on vital
time to progression.
†P value for interaction between BMI and TBI 5 0.0085.(with, in successive analyses, the BSA calculated using
ABW, adjusted IBW, or IBW), or as the dose per kg of
ABW. For the absolute dose of melphalan, the hazard
ratio associated with a 10-mg increase in dose was 0.99
(95% CI: 0.98-1.01); the hazard ratios per 10 mg/m2
increase in dose were 1.00 (95% CI: 0.97-1.04), 0.99
(95% CI: 0.96-1.02) and 1.01 (95% CI: 0.99-1.04)
when BSA was calculated with actual, adjusted
ideal, and IBW, respectively; and the hazard ratioession 95% Confidence Interval P Value
Poverall 5 .055
0.70 1.03 .10
0.69 1.10 .25
0.90 1.55 .23
Poverall 5 .027
0.61 1.49 .84
0.28 1.03 .06
0.22 0.86 .016
Poverall 5 .002
1.20 1.73 <.001
0.86 1.31 .58
0.69 1.32 .77
0.75 1.70 .58
Poverall 5 .009
0.97 1.39 .10
1.18 2.86 .007
onse; PR, partial response.
status, and 17 patients were excluded because of missing information on
Table 4. Multivariate Analysis of Overall Survival
N† Hazard Ratio for Mortality 95% Confidence Interval P Value
BMI:*
Melphalan alone
Normal 248 1.00 Poverall 5 .23
Overweight 405 0.85 0.68 1.07 .17
Obese 177 0.82 0.62 1.09 .17
Severely obese 100 1.09 0.78 1.51 .62
Melphalan/TBI
Normal 44 1.00 Poverall 5 .015
Overweight 62 1.32 0.81 2.13 .26
Obese 21 0.54 0.27 1.10 .09
Severely obese 22 0.55 0.25 1.22 .14
Other significant covariates:
Durie-Salmon stage at diagnosis
I 65 1.00 Poverall 5 .0033
II 321 1.43 0.93 2.21 .10
III 657 1.86 1.23 2.82 .0034
missing 27 1.47 0.73 2.98 .28
Karnofsky score
#90 357 1.00 Poverall 5 .015
>90 674 0.78 0.65 0.93 .005
missing 39 0.71 0.44 1.16 .18
No. of prior therapies
0-1 708 1.00 Poverall 5 .0002
2 272 1.29 1.06 1.57 .012
>2 90 1.76 1.30 2.37 .0002
Sensitivity to chemo
Sensitive 828 1.00
Resistant 242 1.23 1.01 1.50 .041
BMI indicates body mass index; TBI, total body irradiation.
*P value for interaction between BMI and TBI 5 .012.
†This model is stratified on creatinine level at time of transplantation. Seven patients were excluded from this model for missing information on vital
status, 1 for death at the time of transplantation, and 9b because of missing information on sensitivity to chemo.
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1.16) when the dose was calculated per kg of ABW.
Repeating these analyses in the population of obese
and severely obese patients yielded similar results
(data not shown). Therefore, none of these analyses
showed any effect of variation in chemotherapy dose
on PFS.
Dose of TBI
We further investigated the reason for the restric-
tion of the effect of obesity to TBI-containing trans-
plantations. Most patients received a planned dose of
12 Gy (65% of normal and overweight, 74% of obese,
and 68%of severely obese patients), with a few patients
receiving 13 Gy (9% of normal and 10% of over-
weight, none of the obese or severely obese), 10-11
Gy (12% of normal, 13% of overweight, 16% of obese,
and 23% of severely obese), or\10 Gy; these differ-
ences were not significant (overall P value .75). There
was no discernible effect of TBI dose on PFS and no
evidence that the TBI dose confounded the effect of
obesity on PFS (data not shown).DISCUSSION
We have analyzed a large cohort of patients receiv-
ing high-dose melphalan-based AutoHCT for initialtherapy of myeloma. We did not find any differences
in outcome between obese and nonobese patients re-
ceiving a conditioning regimen of single-agent mel-
phalan. This finding suggests that obese patients can
receive high-dose melphalan AutoHCT without in-
creased treatment-related mortality and that obesity
should not be a contraindication to undergoing autol-
ogous transplantation.
Participating transplant centers reported total
melphalan doses administered but not information re-
garding the specific intention of treating physicians in
adjusting melphalan doses for individual patients. We
therefore do not knowwhich patients received reduced
doses based on IBW or adjusted IBW (or with calcu-
lated BSA capped to define a maximum allowable
dose). Previously published literature suggests that
variation in approach to dose adjustment is substantial
[34,35], and a variety of dosing strategies were likely
used in the patients in our study. This is clear from
the significant minority of obese patients in our
cohort who received doses within 10% of a full dose
calculated according to ABW (44% of obese patients
and 22% of severely obese patients). Our results
suggest that current strategies used in clinical
practice for adjusting melphalan doses in obese
patients (ie, calculating doses based on ideal or
adjusted IBW for some but not all patients) do not
appear to impair outcomes in this population.
Figure 1. Estimated probabilities of time-to-event outcomes based on final multivariate models. Overall and progression-free survival, time to pro-
gression, and time to treatment-related mortality are shown for each BMI category for the entire cohort (first column) and by conditioning regimen
(columns 2 and 3). Some patients are excluded from each model because of missing data on covariates.
Biol Blood Marrow Transplant 17:1765-1774, 2011 1771Obesity and Autologous Transplantation for MyelomaHowever, our data also confirm previous findings that
dosing strategies in obese patients are variable, with
a wide range of melphalan doses. Further research to
determine optimal dosing for these patients may be
helpful in decreasing variability in toxicity and efficacy.
Our results also show that among patients receiving
melphalan with TBI, a higher BMI was associated with
improved PFS,OS, and risk of progression.The reason
for the restriction of a beneficial effect of obesity to the
TBI conditioning regimen is unclear. One possible ex-
planation is that the distribution of TBI dose through
body tissues differs between obese and thin patients.
Standard practice calculates the target radiation dose
at the midplane of the body, but deposition of the
radiation dose is not uniform, and increasing body
size (as measured by anteroposterior distance) requires
higher doses delivered to themore superficial tissues to
achieve the same midplane dose [36]. Differences in
body fat content are generally assumed to have littledifference on dose distribution, but it is possible that
obese patients’ increased size would result in higher
doses to the bone marrow, leading to improved anti-
myeloma efficacy. It is also possible that the metabo-
lism of tumor cells in obese patients differs in a way
that makes the cancer more susceptible to radiation,
leading to a simple effect of increased radiation efficacy
in obese patients. We cannot completely exclude con-
founding as an explanation for the improved outcomes
in obese patients receiving TBI, in that obese trans-
plant recipients may have had less aggressive myeloma
or less cancer cachexia in ways not captured by our
measured covariates. Such differences would not ac-
count for a differential effect restricted to TBI condi-
tioning unless selection of the conditioning regimen
at some centers depended on a combination of body
size and overall health, so that TBI was offered to
healthier obese patients. However, we found no evi-
dence of confounding by any characteristics of the
Figure 2. Melphalan dosing by BMI. Median (line), 25th-75th percentile (box), and 5th-95th percentile (whiskers) of melphalan dose, expressed as total
dose, dose per m2 (using ABW, IBW, or adjusted IBW), or dose per kilogram. Reference lines indicate full doses (200 mg/m2 alone or 140 mg/m2 with
TBI). In each panel, P\.001 for overall differences among the BMI groups.
1772 Biol Blood Marrow Transplant 17:1765-1774, 2011D. T. Vogl et al.patients, their myelomas, or their therapies, although
we were limited by the lack of complete data on some
of the newer prognostic factors such as International
Stage or beta-2 microglobulin levels. We therefore
conclude that further investigation is warranted to
fully understand the effect of obesity in the setting
of TBI and determine whether delivering therapeutic
doses to marrow-containing structures could be fur-
ther optimized.
The regimen of melphalan and TBI is no longer
commonly used for myeloma because of evidence of
similar results and less toxicity with melphalan alone
[37]. This may limit further investigation into this
regimen in the setting of myeloma therapy, but TBI
is used in patients with some types of lymphoma
and commonly in patients with acute leukemia
undergoing allogeneic HCT. Further research will
be necessary to determine whether the associationbetween obesity and outcomes applies to these other
patient populations, for whom improved targeting
of radiation doses could lead to better treatment
outcomes.
Our results differ from previously published stud-
ies of AutoHCT, but no other study has examined the
same specific population. Two studies (in acute mye-
loid leukemia or lymphoma) have found obesity to be
associated with worse posttransplantation outcomes
[21,24], but analysis of a larger lymphoma cohort
from the CIBMTR found no difference in outcomes
[23]. Other studies have been limited by the inclusion
of multiple diseases, different conditioning regimens,
or both autologous and allogeneic transplantations,
and have found either no effect of obesity [18] or an
increased risk of NRM [19]. None of these trials exam-
ined results in patients with myeloma or examined sep-
arately outcomes using TBI conditioning regimens,
Biol Blood Marrow Transplant 17:1765-1774, 2011 1773Obesity and Autologous Transplantation for Myelomaand their results are therefore not directly comparable
with the results of our study.
Our study found no evidence that variability in
chemotherapy dosing among obese patients leads to
differences in outcomes, nor that obese patients are
at higher risk of treatment-related mortality or disease
progression. In fact, among patients receiving melpha-
lan and TBI, obese patients had a lower risk of relapse.
The current commonly used strategy of reducing mel-
phalan doses (calculating based on ideal or adjusted
IBW) does not appear to impair outcomes for obese
patients, and obesity should not exclude patients
from consideration of autologous transplantation.
Further research is necessary to optimize dosing of
both chemotherapy and radiation in obese patients.ACKNOWLEDGMENTS
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